Health
Nanobodies that neutralize SARS-CoV-2 – EurekAlert
Two separate studies have identified nanobodies – which could be produced less expensively than monoclonal antibodies – that bind tightly to the SARS-CoV-2 spike…
Two separate studies have identified nanobodies – which could be produced less expensively than monoclonal antibodies – that bind tightly to the SARS-CoV-2 spike protein and efficiently neutralize SARS-CoV-2 in cells. “The combined stability, potency, and diverse epitope engagement of our … nanobodies … provide a unique potential prophylactic and therapeutic strategy to limit the continued toll of the COVID-19 pandemic,” write authors on one paper (Michael Schoof et al.) In the battle against…
-
Business14 hours agoBattle of the ASX ETFs: Why has VGS outperformed VTS this year?
-
Business10 hours ago1 ASX dividend stock down 43% I’d buy right now
-
General20 hours agoCoalition abandons ‘end’ to work from home, walks back 41,000 job cuts
-
Business13 hours ago5 things to watch on the ASX 200 on Monday 7 April 2025